» Articles » PMID: 31037076

Short-Term Side Effects of Low Dose Valproate Monotherapy in Epileptic Children: A Prospective Study

Overview
Specialty Pediatrics
Date 2019 May 1
PMID 31037076
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Considering the common use of valproate among children, we investigated the short-term side-effects of low dose valproate monotherapy in epileptic children.

Materials & Methods: In this prospective study, 209 epileptic children (48.3% male, mean age: 7.02 ± 3.13 yr) on low therapeutic dose of valproate monotherapy (20-30 mg/kg/d) were enrolled during 2014-2015 in Isfahan Pediatric Neurology Clinic, Isfahan University of Medical Sciences, Isfahan, Iran and side-effects were evaluated through frequent clinical visits and laboratory tests during 6 months of valproate therapy.

Results: Weight gain was reported in 53.1% of patients. Decreased appetite was seen in 11% of patients, more frequent in younger cases (=0.006). Abdominal pain, nausea/vomiting, diarrhea, and constipation were reported in 16.3%, 2.4%, 1.4%, and 1% of patients, respectively. Headache, tremor, dizziness, abnormal color vision, myoclonus, and bruxism were seen in 5.7%, 1.4%, 1%, 1%, 1%, and 0.5% of patients, respectively. Enuresis, hair loss, and skin rash were reported in 8.1%, 6.7%, and 0.5% of patients, respectively. Thrombocytopenia, impaired liver function tests, and leukopenia occurred in 1%, 1%, and 0.5% of patients, respectively.

Conclusion: Low dose valproate monotherapy may cause numerous side-effects, mostly not life-threatening and requiring no action. Besides more reported complications, we observed decreased appetite (among younger patients), enuresis, and abnormal color vision which are onlybriefly discussed in the literature and need to be addressed more.

Citing Articles

Antiseizure Drugs and Movement Disorders.

Saenz-Farret M, Tijssen M, Eliashiv D, Fisher R, Sethi K, Fasano A CNS Drugs. 2022; 36(8):859-876.

PMID: 35861924 DOI: 10.1007/s40263-022-00937-x.


Elucidating the Potential Side Effects of Current Anti-Seizure Drugs for Epilepsy.

Akyuz E, Koklu B, Ozenen C, Arulsamy A, Shaikh M Curr Neuropharmacol. 2021; 19(11):1865-1883.

PMID: 34525933 PMC: 9185788. DOI: 10.2174/1570159X19666210826125341.

References
1.
Novak G, Maytal J, Alshansky A, Eviatar L, Siddique Q . Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol. 1999; 14(8):490-5. DOI: 10.1177/088307389901400802. View

2.
Verrotti A, Trotta D, Morgese G, Chiarelli F . Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2003; 17(4):367-73. DOI: 10.1023/a:1021918104127. View

3.
Wirrell E . Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol. 2003; 28(2):126-9. DOI: 10.1016/s0887-8994(02)00505-2. View

4.
Verrotti A, Lobefalo L, Priolo T, Rapinese M, Trotta D, Morgese G . Color vision in epileptic adolescents treated with valproate and carbamazepine. Seizure. 2004; 13(6):411-7. DOI: 10.1016/j.seizure.2003.09.006. View

5.
Gerstner T, Teich M, Bell N, Longin E, Dempfle C, Brand J . Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006; 47(7):1136-43. DOI: 10.1111/j.1528-1167.2006.00587.x. View